A single blood test can predict a heart attack before symptoms start

Health · Published 3 November 2026 Swipe more like this →

In short: Cardiac biomarkers like troponin and myoglobin can detect heart damage hours before symptoms appear. These tests are changing how doctors diagnose heart attacks and assess risk. Swipe to see which markers are most reliable and why early detection matters.

Cardiac biomarkers are revolutionizing the diagnosis of heart attacks by detecting myocardial injury before symptoms appear. Troponin, in particular, is now the gold standard for diagnosing heart attacks, with high-sensitivity assays allowing earlier detection. These tests can identify damage hours after a heart attack begins, making them crucial for timely intervention. However, they are not perfect—high-sensitivity troponin can produce false positives, especially in patients who present more than two hours after symptoms start. This means that while these tests are highly effective at ruling out heart attacks, they can sometimes lead to unnecessary anxiety or further testing.

Other biomarkers, such as myoglobin and CK-MB, offer earlier detection but lack the specificity of troponin. Myoglobin, for instance, can be detected in the blood as early as one hour after a heart attack, but it is also present in skeletal muscle, making it less reliable. CK-MB, while more specific to cardiac tissue, is being largely replaced by troponin due to its superior sensitivity and specificity. Although troponin tests are now more commonly used, CK-MB remains useful for identifying reinfarctions or in cases where troponin assays are unavailable. These markers work together to provide a more comprehensive picture of cardiac health, helping doctors distinguish between different types of heart damage and assess the risk of future events.

Beyond diagnosis, biomarkers are also used for risk stratification. For example, high levels of lipoprotein A (LPA) are associated with a higher genetic predisposition to cardiovascular events, making it an important marker in assessing long-term risk. Similarly, non-HDL cholesterol, calculated as total cholesterol minus HDL, is a better predictor of risk than individual cholesterol measurements. These markers, along with inflammatory biomarkers like C-reactive protein (CRP), help doctors tailor treatment plans and monitor the effectiveness of interventions. The use of these biomarkers is part of a broader shift toward personalized medicine, where treatment is based not just on symptoms but on the underlying biological markers of disease.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• The tiny protein that signals when your heart muscle is failing
• The world's leading killer often announces itself first with a heart attack
• Heart muscle dies when a coronary artery suddenly loses flow
• When the heart muscle fails, the entire system faces a structural crisis
• Half of cardiac arrests give no warning before the pulse vanishes
• Can we find meaning when life's certainties vanish?
• Does cannabis actually help with insomnia?
• Why the clothes must change, not your body
• BPH treatments range from pills to lasers, but none are perfect
• Can a dose of humor and illustration actually help patients manage physical pain?
• The urinary system isn't just about peeing—it's a complex network of organs.
• Cancer cells may be using electricity as a secret language

More in Health · Latest · A–Z · All topics